Sera Prognostics, Inc. reported its financial results for the second quarter of 2026, revealing a modest increase in revenue but continued operating losses. The company generated $30,000 in revenue for the three months ended June 30, 2026, compared to $17,000 for the same period in 2025. For the first half of 2026, total revenue was $44,000, down from $55,000 in the prior year. The net loss for the second quarter was $9.1 million, an increase from $8.0 million in the same quarter last year, while the loss for the first half of 2026 was $17.5 million, compared to $16.2 million in 2025.
Operating expenses for the second quarter totaled $10.0 million, up from $9.3 million in the prior year, driven by increased selling and marketing costs, which rose to $2.2 million from $1.8 million. Research and development expenses also saw a slight increase, totaling $3.5 million compared to $3.3 million in the previous year. The company’s accumulated deficit as of June 30, 2026, stood at $329.3 million, reflecting ongoing investments in its PreTRM test and other pipeline products.
In terms of strategic developments, Sera Prognostics has undergone a restructuring aimed at reallocating resources towards the commercialization of its PreTRM test, which predicts the risk of preterm birth. This restructuring included a workforce reduction of approximately 18%, or 14 employees, and is expected to result in $1.3 million in severance costs. The company has also launched a fourth partnership program to enhance the implementation of the PreTRM test and has engaged in active discussions with over 20 payers across multiple states to improve market access.
Operationally, Sera Prognostics is focusing on expanding its market presence and enhancing the adoption of its PreTRM test. The company reported that it has made significant strides in payer engagement, particularly following the enactment of legislation in Illinois mandating Medicaid coverage for proteomic blood tests related to preterm birth risk. The company’s leadership team has been strengthened to support these commercialization efforts, with new hires in key positions aimed at driving growth in the diagnostics space.
Looking ahead, Sera Prognostics anticipates that its existing cash and cash equivalents will be sufficient to fund operations through 2029, despite the expectation of continued operating losses. The company is committed to pursuing additional funding opportunities and expanding its commercial activities, particularly as it seeks to leverage the clinical evidence from its studies to drive adoption of the PreTRM test among healthcare providers and payers.
About SERA PROGNOSTICS, INC.
Sera Prognostics specializes in women’s health by developing blood-based biomarker tests and predictive analytics to improve pregnancy outcomes. Its core product, the PreTRM test, accurately predicts preterm birth risk, enabling proactive interventions. The company leverages proprietary proteomics, bioinformatics, and extensive biobanks to address unmet needs in maternal-fetal medicine, targeting healthcare providers, payers, and pregnant women worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov